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Abstract
The p63 transcription factor, homolog to the p53 tumor suppressor gene, plays a crucial role in epidermal and limb
development, as its mutations are associated to human congenital syndromes characterized by skin, craniofacial and limb
defects. While limb and skin-speciﬁc p63 transcriptional targets are being discovered, little is known of the post-translation
modiﬁcations controlling ΔNp63α functions. Here we show that the p300 acetyl-transferase physically interacts in vivowith
ΔNp63α and catalyzes its acetylation on lysine 193 (K193) inducing ΔNp63α stabilization and activating speciﬁc transcriptional
functions. Furthermore we show that Fibroblast Growth Factor-8 (FGF8), a morphogenetic signaling molecule essential for
embryonic limb development, increases the binding of ΔNp63α to the tyrosine kinase c-Abl as well as the levels of ΔNp63α
acetylation. Notably, the natural mutant ΔNp63α-K193E, associated to the Split-Hand/Foot Malformation-IV syndrome, cannot
be acetylated by this pathway. This mutant ΔNp63α protein displays promoter-speciﬁc loss of DNA binding activity and
consequent altered expression of development-associated ΔNp63α target genes. Our results link FGF8, c-Abl and p300 in a
regulatory pathway that controls ΔNp63α protein stability and transcriptional activity. Hence, limb malformation-causing p63
mutations, such as the K193E mutation, are likely to result in aberrant limb development via the combined action of altered
protein stability and altered promoter occupancy.
Introduction
The p63 transcription factor, highly related to the p53 and p73
transcription factors, plays a central role during development
of the embryonic ectoderm and derived structures. p63 is ex-
pressed in the embryonic ectoderm and in the proliferating
stem cells of the adult epidermis, breast and oral epithelium
(1,2). Accordingly, p63 null mice show lack of epidermis stratiﬁ-
cation which causes death at birth, absence of nails and hairs,
sweat and mammary glands and severe defects in limb and
craniofacial development (3,4).
The limbdefects observed in p63−/−mice are highly reminiscent
of ectrodactily found in patients affected by the Ectrodactily-
Ectodermal Dysplasia-Cleft palate syndrome (EEC) or in non-
syndromic Ectrodactily, also known as Split-Hand Foot
Malformation (SHFM) type-IV. Ectrodactily is characterized by
the absence of the central rays of the limbs, resulting in a deep
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medial cleft, missing or hypoplastic central ﬁngers and fusion of
the remaining ones (5–8), and has been associated with develop-
mental failure of the Apical Ectodermal Ridge (AER) a transitory
pluri-stratiﬁed ectodermal region required for limb outgrowth,
and for the expression of key signaling molecules (1,2,5–9).
p63 is at the center of a complexmolecular network. However,
its regulation and tissue distribution remain issues not fully
understood. The p63 gene encodes for at least ten protein iso-
forms, which differ in their amino and carboxy-terminal regions
as a consequence of alternative transcription start site and alter-
native splicing, respectively (10,11), with ΔNp63α being the most
expressed isoform in the embryonic ectoderm. All p63 isoforms
share with p53 and p73 homology in the DNA binding and the
oligomerization domains (12–15), and indeed p53 and p63 regu-
late a number of common transcriptional targets, in particular
those related to cell-cycle control. However, p63-speciﬁc target
genes are known that justify its speciﬁc role in ectodermdevelop-
ment and epidermis stratiﬁcation, and also explain the speciﬁc
set of human diseases associated with p63 mutations (16–18).
Interestingly, while somemutations of the p63 gene occurring
in the DNA Binding Domain (DBD) coding sequence (such as the
R279Hmutation) are causative of the EEC syndrome, which com-
prises ectrodactyly and several other skin and craniofacial devel-
opmental defects, others (such as the K193E mutation) result in
non-syndromic ectrodactyly (or SHFM-type IV), with little or no
skin/craniofacial anomalies (7,8). The logical question that arises
is: why the EEC- and the SHFM-associated mutations cause limb
developmental malformations, while p63 mutations found in
AEC patients (i.e. the L518F mutation), localized in the SAM do-
main of the ΔNp63α protein, do not affect limb development?
One possibility is related to the ability of the peptidyl-prolyl
isomerase Pin1 to negatively regulate ΔNp63α stability, and to
the activity of the key limb morphogen Fibroblast Growth Fac-
tor-8 (FGF8) (19–22) to counter-act this function (23). Mutant p63
proteins are differentially sensitive to Pin1-induced degradation
(23). However, the correlation between speciﬁc p63 mutations,
their stability, transcriptional activity and the onset of limb de-
velopmental anomalies remains not fully resolved.
It is becoming increasingly evident that the distinct functions
of wild-type and mutant p63 protein(s) might reside not only in
their speciﬁc DNA binding activity but also in their post-transla-
tional modiﬁcations such as sumoylation, phosphorylation and
ubiquitylation (24–27). These modiﬁcations modulate ΔNp63α
half-life, the speciﬁcity and efﬁciency of protein–protein interac-
tions and overall modulate the transcriptional activity of the pro-
tein. The elucidation of these ‘upstream’ regulatory events is
required for a full comprehension of the molecular network cen-
tered on p63, to explain the genotype–phenotype correlations ob-
served in patients affected by syndromes associated to p63
mutations.
p53 and/or p73 protein activity and stability are ﬁnely regu-
lated by several post-translational modiﬁcations (28–30), among
which acetylation seems to play a pivotal role in regulating
their biological functions (29,31–33). Acetylation is a reversible
modiﬁcation, catalyzed by histone acetyl-transferases, of lysine
residues of a target protein and its function in transcriptional ac-
tivation is well accepted (34). p73 is acetylated by p300 on lysines
located in the DNA binding and oligomerization domains in re-
sponse to DNA damage (35); acetylation enhances p73 ability to
bind and activate proapototic target genes (36). Furthermore,
p73–p300 interaction requires the activity of Pin1 that induces
p73 conformational changes upon phosphorylation by the tyro-
sine kinase c-Abl (37). Acetylation of p53 is enhanced in response
to DNA damage and well correlates with p53 stabilization and
activation: indeed, acetylation of p53 antagonizes the MDM2 ubi-
quitin-ligase activity that keeps p53 protein at low levels in nor-
mal conditions. Moreover, acetylation of p53 by p300 was found
to promote its sequence-speciﬁc DNA binding (31–33,38).
All considered, we set forth to examine ΔNp63α acetylation in
the context of naturally occurring ΔNp63α missense mutations
associated to SHFM-IV: one suchmutation causes lysine 193 sub-
stitution with glutamic acid (K193E) (7,8). We noted that lysine
K164 in p53, acetylated by p300 (38), correspond to K193 in
ΔNp63α. Thus we raised the hypothesis that wild-type ΔNp63α
could be acetylated by p300 on K193, and that mutations of this
residue could prevent this post-translational modiﬁcation with
important developmental consequences.
Our results are consistent with this hypothesis and, for the
ﬁrst time, we show that FGF8 signaling participates in a regula-
tory pathway promoting the physical interaction of ΔNp63α
with c-Abl and p300, leading to stabilization and transcriptional
activation of ΔNp63α.
Results
Δnp63α is acetylated and stabilized in cultured cells
In order to assess whether p63 could be acetylated in human
cells, we treated the human keratinocytes HaCaT cell line, ex-
pressing endogenous ΔNp63α, with Valproic-Acid (VPA), which
selectively inhibits class I deacetylases, or with Trichostatin-A
(TSA) which inhibits class I and II deacetylases. VPA and TSA
treatments resulted in an increase in ΔNp63α abundance (Fig. 1A).
Similar effects of ΔNp63α accumulation were also obtained
when ΔNp63α was ectopically overexpressed in U2OS cells, a
human osteosarcoma cell line devoid of endogenous p63 expres-
sion (Supplementary Material, Fig. S1). Then, we performed im-
munoprecipitation of endogenous ΔNp63α from total protein
extracts of HaCaT cells treated with TSA. The level of ΔNp63α
acetylation was detected using an antibody against acetylated
lysines: we observed that ΔNp63α is found acetylated at a basal
level, as previously reported (39), and that its acetylation in-
creased upon TSA treatment (Fig. 1B). These results show that
the ΔNp63α protein is acetylated in human cells and that the
acetylation levels of ΔNp63α correlate with its accumulation in
human cells following deacetyl-transferases inhibition.
The acetyl-transferase domain of p300 is required
to induce ΔNp63α protein stabilization
Acetylation of p53 and p73 proteins is required for their stabiliza-
tion and transcriptional activation in response to DNA damage
(31–33,35–38) and the p300 acetyl-transferase is known to be in-
volved in this process (29,35,36,38). To determine whether p300
could acetylate ΔNp63α, we silenced endogenous p300 in HaCaT
cells by transfecting a p300-speciﬁc shRNA plasmid. Depletion of
p300 was clearly detected and, concomitant with p300 reduction,
a signiﬁcant decrease of ΔNp63αwas also observed (Fig. 2A). Con-
versely, when p300 protein levels were increased by transient
overexpression in HaCaT or U2OS cells, ΔNp63α protein was sta-
bilized in a dose-dependent manner (Fig. 2B and C). In contrast, a
construct expressing a mutated variant of p300, with a mutation
affecting the Histone Acetyl-Transferase domain (LY-RR) (36),
failed to stabilize endogenous ΔNp63α in HaCaT cells (Fig. 2B).
These data clearly indicate that p300 and its acetyl-transferase
activity are required for ΔNp63α protein levels regulation.
Accordingly, when we overexpressed ΔNp63α with p300 in
U2OS cells and treated the cells with the protein synthesis
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inhibitor Cycloheximide (CHX), we observed an increase of
ΔNp63α protein half-life (Fig. 3D). We also determined the effect
of p300 silencing on ΔNp63α protein half-life in HaCaT cells, by
transfecting p300-speciﬁc shRNA plasmid and treated the cells
with CHX. As shown in SupplementaryMaterial, Figure S2, the le-
vels of ΔNp63α protein decreased upon p300 silencingwith only a
modest decrease of ΔNp63α half-life upon CHX addition.
P300 interacts with ΔNp63α in human cells and catalyzes
in vitro acetylation of lysine K193
To assess whether the observed stabilization of ΔNp63α by p300
was due to a direct interaction between the two proteins, we
performed co-immunoprecipitation experiment in U2OS cells.
As shown in Figure 3A, ΔNp63α was found in p300 immuno-
complexes, showing that the two proteins can associate in
human cells.
Lysine K164 of the p53 protein, conserved in p63 and p73, is
acetylated by p300 (38). In the ΔNp63α protein this residue corre-
sponds to K193 (Supplementary Material, Fig. S3), mutated in pa-
tients affected by SHFM-IV (i.e. K193E) (7,8). We set forth to
establish whether K193 was acetylated by p300, by carrying out
in vitro acetylation assays using recombinant p300 protein and a
set of synthetic p63 peptides centered on K193. A p53 synthetic
peptide containing lysine K164 known to be acetylated by p300
(38) was used as a positive control. The results show that the
p63 peptide centered on K193 was acetylated in vitro and the
levels of acetylation are similar to those obtained with the p53
peptide (Fig. 3B).
In the same assay we also analyzedmutant p63 peptides car-
rying K193 and K194 substitutions into arginine, either one at a
time or simultaneously, to determine which one (or both) could
be target of the p300 acetyl-transferase activity. As shown in Fig-
ure 3B, p300 acetylates lysine K193: indeed the levels of acetyl-
ation of the p63-K193R mutant were reduced. However we
cannot exclude that also K194 could be acetylated by p300 since
we observed a modest decrease in the level of acetylation of the
p63-K194Rmutant peptide comparedwith thewild-type peptide.
Finally, p300 overexpression in U2OS cells did not induce stabil-
ization of the ΔNp63α-K193R and of the natural ΔNp63α-K193E
mutant, while the ΔNp63α protein was stabilized (Fig. 3C), indi-
cating that the integrity of K193 is required to induce p300-
dependent stabilization of ΔNp63α. Moreover, in contrast to
what observed for the wild-type ΔNp63α, the half-life of the
ΔNp63α-K193Rmutant was not enhanced upon p300 overexpres-
sion in U2OS cells (Fig. 3D).
FGF8 positively regulates ΔNp63α protein stability
inducing its interaction with c-Abl and promoting
ΔNp63α acetylation
During embryonic development, FGF8 acts as a signaling peptide
essential for growth, morphogenesis and patterning of the limb
buds (9,19–22). We have recently shown that FGF8 exerts a
Figure 1. The ΔNp63α protein is acetylated in human keratynocytes. (A) Western Blot (WB) analysis of whole HaCaT cell extracts treated with increasing amounts of TSA
(5 ng/ml and 10 ng/ml) for 5 h or VPA (0.5 m and 1 m) for 3 h. (B)Whole cell extracts fromHaCaT cells treatedwith 5 ng/ml of Trichostatin (TSA) for 5 hwere analyzed by
immunoprecipitation of endogenous ΔNp63αwith an anti-p63 antibody followedbyWBanalysiswith an anti-acetylated lysines. U2OS cells, not expressing p63, were used
as negative control.
Figure 2. The acetyl-transferase domain of p300 is required to induce ΔNp63α protein stabilization. (A) WB analysis of whole HaCaT cell extracts transiently transfected
with increasing amounts (20 ng and 40 ng) of shp300 or shLuc expression vectors (B) WB analysis of HaCaT whole cell extracts transiently co-transfected with equal
amount of ΔNp63α expression vectors (30 ng) and increasing amounts of p300 encoding plasmids (p300 (WT) or p300-LY-RR, mutated in the HAT domain (10 and
20 ng). (C) WB analysis of U2OS whole cell extracts transiently co-transfected with equal amount of ΔNp63α expression vectors (30 ng) and increasing amounts of p300
expression vectors (10 and 20 ng).
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stabilizing function on the ΔNp63α protein, by preventing its
interactionwith Pin1 that targets ΔNp63α protein for proteasomal
degradation (23). We raised the hypothesis that FGF8 may
stabilize the ΔNp63α protein, via p300-mediated acetylation of
ΔNp63α, and that the limb malformation-associated p63 K193E
mutation may pose an obstacle to this regulation.
Figure 3. p300 interacts with ΔNp63α in human cells and catalizes in vitro acetylation of lysine K193. (A) U2OS whole cell extracts transiently co-transfected with ΔNp63α
and p300 were analyzed by immunoprecipitation with an anti-p300 antibody followed by WB analysis with an anti-p63 antibody. U2OS cells, not transfected with p63
encoding plasmid were used as negative control. (B) In vitro acetylation assay performed according to the HAT assay kit protocol (Active Motif ) with an H4 peptide and
p53 peptides as positive controls, H4 plus anacardic acid 15 μM (an inhibitor of acetyl-transferase activity used as a negative control) and p63 peptides (peptide sequences
are indicated). (C)WBanalysis ofU2OSwhole cell extracts transiently co-transfectedwith ΔNp63α, ΔNp63α-K193E, ΔNp63α-K193Rexpression vectors (30 ng) and increasing
amounts of p300 encoding plasmid (10 and 20 ng). (D)WB analysis of U2OSwhole cell extracts transiently co-transfectedwith ΔNp63α, ΔNp63α-K193R and p300 expression
vectors (30 ng and 5 ng respectively). 24 h after transfection protein half-life was measured by treating cells with 10 μg/ml of CHX.
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Figure 4. FGF8 positively regulates ΔNp63α protein stability inducing its interaction with c-Abl and promoting ΔNp63α acetylation. (A) WB analysis of HaCaT whole cell
extracts treated with increasing amounts of FGF8 (0.5 ng/ml and 1 ng/ml) for 3 h. (B) WB analysis of HaCaT whole cell extracts stably transfected with an shRNA against
c-Abl or shLuc plasmids, treated with increasing amounts of FGF8 (0.5 ng/ml and 1 ng/ml) for 3 h. (C) WB analysis of HaCaT cells treated with increasing amounts of FGF8
(0.5 ng/ml and 1 ng/ml) or pre-treated for 30 min with Imatinib (10 μM) followed by FGF8 treatment for 3 h. (D) U2OS whole cell extracts transiently co-transfected with
either ΔNp63α or ΔNp63α-3Y (10 μg) and p300 (5 μg), and then analyzed by immunoprecipitation with an anti-p300 antibody followed by WB analysis with an anti-p63
antibody. (E) HaCaT whole cell extracts treated with FGF8 (0.5 ng/ml) or DMSO for 3 h were analyzed by immunoprecipitation with anti-p63 antibodies followed by WB
analysis with the indicated antibodies. U2OS cells, not expressing p63 were used as negative control. (F) WB analysis of U2OS whole cell extracts transiently
transfected with ΔNp63α or ΔNp63α-K193E encoding plasmids (30 ng). 24 h after transfection U2OS cells were treated with increasing amounts of FGF8 for 2 h (0.5 ng/
ml and 1 ng/ml). (G) WB analysis of total proteins extracts from forelimbs isolated from wild-type mouse embryos at E11.5, cultured whole-mount for 48 h in the
absence or presence of recombinant FGF8 (0.5 μg/ml and 1 μg/ml).
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First, we treated HaCaT cells with increasing amounts of sol-
uble FGF8 that resulted in efﬁcient ΔNp63α protein stabilization
as expected (Fig. 4A).
One of the down-stream effector of FGFs is the tyrosine kinase
c-Abl: indeed, c-Abl is activated by FGF2 treatment (40). c-Abl is
also a key regulator of the p53 family members (29,37,41–45). To
verify whether c-Abl was required to induce the observed FGF8-
mediated stabilization of ΔNp63α, we stably silenced endogenous
c-Abl expression in HaCaT cells and then treated these cells with
either FGF8 or FGF2. c-Abl silencing abolished ΔNp63α stabiliza-
tion induced by either FGF8 (Fig. 4B) or FGF2 (data not shown),
suggesting that FGFs stabilization of ΔNp63α requires the pres-
ence of the c-Abl protein. In order to verify whether the tyrosine
kinase activity of c-Abl was required for the FGF8-mediated sta-
bilization of ΔNp63α, we treated HaCaT cells with Imatinib, an in-
hibitor of c-Abl tyrosine kinase activity. As shown in Figure 4C,
FGF8-mediated stabilization of ΔNp63α was prevented by Imati-
nib pre-treatment. Furthermore, the ΔNp63α-3Y mutant protein,
with the three tyrosines known to be phopshorylated by c-Abl
mutated into phenylalanin (44,45), was not stabilized by FGF8
treatment (Supplementary Material, Fig. S4).
To verify whether c-Abl was promoting the interaction be-
tween ΔNp63α and p300, we performed co-immunoprecipitation
experiments of p300 with wild-type ΔNp63α or with the ΔNp63α-
3Y mutant. As shown in Figure 4D, the ΔNp63α-3Y mutant dis-
played a drastically reduced interaction with p300 compared
with wild-type ΔNp63α. Furthermore p300 overexpression did
notmodulate ΔNp63α-3Yprotein levels (SupplementaryMaterial,
Fig. S5).
In order to verify whether FGF8, c-Abl and p300 were linked
together in the same regulatory pathway, promoting ΔNp63α
stabilization, we treated HaCaT cells with FGF8 and performed
co-immunoprecipitation of ΔNp63α; we observed a great increase
in ΔNp63α-c-Abl interaction and in the levels of ΔNp63α acetyl-
ation upon FGF8 treatment (Fig. 4E). Interestingly, we found
that the signaling cascade activated by FGF8 was not active on
the SHFM-IV-causing ΔNp63α-K193E mutant protein. Indeed as
shown in Figure 4F, FGF8 treatment in U2OS cells did not induce
ΔNp63α-K193E stabilization, clearly resembling the results ob-
tained by p300 overexpression on this mutant (Fig. 3C). All
these results indicate that c-Abl and p300 are linked together in
a cascade, activated by FGF8, regulating ΔNp63α protein stability.
To verify if FGF8 and c-Abl are required to modulate not only
ΔNp63α protein stability, but also its transcriptional activity, we
performed luciferase assay in U2OS cells transiently transfected
with the DLX5 promoter, a known ΔNp63α transcriptional target
in the AER cells of developing limbs (46). FGF8, Imatinib and Im-
atinib followed by FGF8 treatment were used. Interestingly, when
we inhibited c-Abl kinase activity, ΔNp63αwas unable to transac-
tivate the DLX5 promoter even in the presence of FGF8 treatment
(Supplementary Material, Fig. S6). These data suggest that the
c-Abl kinase activity was required to transduce the signal
induced by FGF8 leading to ΔNp63α stabilization and transcrip-
tional activation. Similar results were also obtained with the
EGFR promoter (18, data not shown).
Finally, in order to assess if such mechanism could be rele-
vant in vivo, e.g. the developing limb bud, we adopted an ex vivo
method by culturing the embryonic limb buds obtained from
wild-type mouse embryos at the age E10.5, and maintained
whole-mount for 48 h (47). During the culture time, puriﬁed re-
combinant FGF8 was added to the medium at physiological
doses, then the tissues were collected and analyzed by Western
blot analyses for the abundance of ΔNp63α protein. Compared
with untreated limbs, addition of FGF8 resulted in a clear
accumulation of the ΔNp63α protein (Fig. 4G), indicating that
FGF8 efﬁciently stabilizes, and most likely activates, ΔNp63α in
the context of the limb embryonic tissue.
The K193E mutation alters ΔNp63α transcriptional
activity in a promoter-speciﬁc manner
In order to verify whether p300 could act as a ΔNp63α co-activator
we performed luciferase-reporter assayswith theDLX5promoter.
Interestingly, we observed that p300 co-transfection greatly en-
hanced the transcriptional activity of ΔNp63α, while the tran-
scriptional activity of the ΔNp63α-K193E mutant could not be
enhanced by p300 overexpression (Fig. 5A).
ΔNp63α transcriptional activity was impaired by the K193E
mutation also on other ΔNp63α target genes involved in develop-
ment, EGFR andDLX6 (Fig. 5B) (18,46).We then examinedwhether
the K193E mutation could alter ΔNp63α transcriptional activity
on genes not directly required for limb development; for this
aim we used the p57KIP2 and ADA promoters, known to be in-
volved in p63-dependent cell-cycle regulation (48,49). Interest-
ingly, we found that the ΔNp63α-K193E mutant behaved as the
wild-type ΔNp63α protein on both promoters (Fig. 5C), suggesting
that the K193Emutation selectively alters ΔNp63α transcriptional
activity.
To further characterize the transcriptional activity of the
ΔNp63α-K193E mutant, we performed real-time, quantitative
qPCR analyses in U2OS cells stably transfected with either the
wild-type ΔNp63α or the ΔNp63α-K193E expression vectors. Inter-
estingly, we conﬁrmed that the ΔNp63α-K193E mutant over-
expression results in altered expression of ΔNp63α target genes
involved in development and apoptosis such as PERP, CASP10,
EGFR (18,50) while it behaves like the wild-type ΔNp63α on p53
(Fig. 6A). Taken together, these data clearly show that the
K193E mutation alters the transcriptional activity of ΔNp63α in
a gene-speciﬁc manner.
Next we tested whether the ΔNp63α-K193E mutant displayed
altered DNA binding ability by Chromatin Immunoprecipitation
(ChIP) assay of U2OS cells stably transfected with the wild-type
ΔNp63α or with the ΔNp63α-K193E expressing vectors; the pro-
teins were correctly expressed (Fig. 6B). We observed that the
ΔNp63α-K193E mutant was not efﬁciently recruited on the Re-
sponsive Elelments (RE) of genes relevant for developmental
and apoptotic processes (PERP, CASP10 and EGFR) while it was
normally recruited on RE of the p53 gene, involved in cell cycle
regulation (Fig. 6C).
In conclusion, the K193Emutation alters the ability of ΔNp63α
to bind speciﬁc RE sequences resulting in altered transcriptional
regulation of genes involved in the regulation of development
and apoptotic processes.
Discussion
The p63 transcription factor is emerging as a master regulator of
development and differentiation of ectoderm derived cells and
tissues. In the last few years much attention has been paid to
the analysis and identiﬁcation of p63 transcriptional targets,
their tissue and process speciﬁcity and how mutations in p63
affect its down-stream transcriptional properties (16–18,51,52).
Clearly, this is only part of the full story. Indeed, more recently
several p63 post-translational modiﬁcations have been recog-
nized, acting either during response to DNA damage, differenti-
ation or embryonic development (24–27). The full spectrum of
these modiﬁcations, likely able to regulate stability and activity
of the ΔNp63α protein, are not fully understood.
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Figure 5. The K193E mutation alters ΔNp63α transcriptional activity in a promoter-speciﬁc manner. (A) Luciferase assay performed on U2OS cells transiently co-
transfected with the −1200 bp DLX5 promoter (200 ng) in the presence of ΔNp63α or ΔNp63α-K193E (50 ng) with increasing amounts of p300 (10 and 20 ng) expression
vectors. Each histogram bar represents the mean of three indipendent transfection duplicates. Standard deviation are indicated. (B) Luciferase assay performed in
U2OS cells transiently co-transfected with the DLX6, and EGFR reporter promoters (200 ng) in the presence of increasing amounts of ΔNp63α or ΔNp63α-K193E (50 and
100 ng) plasmids. (C) Luciferase assay performed on U2OS cells transiently co-transfected with the p57kip2, and ADA reporter promoters (200 ng) in the presence of
increasing amounts of ΔNp63α or ΔNp63α-K193E (50 and 100 ng) plasmids. For (A–C) cells were lysed 24 h after transfection and luciferase activity was determined.
The basal activity of the reporter plasmid was set to 1. Data are presented as fold activation/repression relative to the sample without effector. Each histogram bar
represents the mean of three independent transfection duplicates. Standard deviations are indicated.
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Here we report that FGF8, c-Abl, p300 and ΔNp63α are func-
tionally linked in amolecular pathwaymodulating ΔNp63α activ-
ity and stability. Our data show that treatments with FGF8, a
signaling molecule essential for limb outgrowth and patterning,
result in increased ΔNp63α protein stability, both in cultured cells
and in embryonic mouse limb buds ex vivo. Based on these data
and previous ﬁndings from our team (23), we propose a model
in which FGF8 promotes the interaction of c-Abl and ΔNp63α,
and that this interaction is required for the consequent
association of ΔNp63α with p300, leading to ΔNp63α acetylation
(scheme in Fig. 7). When such acetylation is inefﬁcient, due to re-
duced FGF8 expression or to mutation of the p300 target lysine
K193 in ΔNp63α, limb developmental defects ensue.
Based onourdata, p300 appears to be an important regulator of
ΔNp63α function during limb development, and in particular the
results point to the possibility that p300 is required to selectively
induce andactivatewith ΔNp63α a set of genes required towarrant
correct limb development. No direct evidence of this is available,
Figure 6. The ΔNp63α-K193Emutant displays an altered DNA binding activity and transcriptional activity on developmental related genes. (A) Expression of CASP10, EGFR,
PERP and p53 was analyzed by Real-Time qPCR in U2OS cells stably transfected with pCDNA3 (empty vector), ΔNp63α or ΔNp63α-K193E cDNAs. (B) ΔNp63α and ΔNp63α-
K193E proteins expressionwas conﬁrmed byWB analysis. (C) Cells used in A and Bwere subjected to ChIP analysis, and the recovered chromatin was ampliﬁedwith PERP,
EGFR, p53 and CASP10-speciﬁc primers.
4192 | Human Molecular Genetics, 2015, Vol. 24, No. 15
in fact the disruption of the p300 gene in the mouse model is em-
bryonic lethal and p300−/− mice arrest their development prior to
the limbbud stage (53). Conversely, the role of acetylationanddea-
cetylation on ΔNp63α are better known, indeed mice double
knock-out for Histone Deacetylase-1 and -2 (HDAC1/HDAC2) display
developmental limb malformations similar to those observed in
p63nullmice (54).HDAC1andHDAC2mediate the repressive func-
tion of ΔNp63α on some of its transcriptional targets (like 14-3-3σ,
p16/Ink4a, p19/ARF) whose down-modulation is essential to
ensure correct development (54). On the other hand, it’s possible
to speculate that Histone acetyl-transferases, such as p300, are
needed to activate p63 target gene expression in concert with
ΔNp63α. Indeed, luciferase-reporter assays indicated that p300
acetylation onK193 of ΔNp63α is required to guarantee an efﬁcient
transcription of genes involved in limb development, such as
human DLX5 and DLX6 (46,55) (Fig. 5A, B).
Figure 7. FGF8 positively regulates ΔNp63αprotein stability inmice embryonic limb buds. FGF8, c-Abl andp300 are component of a regulatory pathway that leads to ΔNp63α
stabilization and transcriptional activation in embryonic limb buds. Exposure of AER cells to FGF8 induces a signaling intracellular cascade that activates c-Abl causing
ΔNp63α phosphorylation on tyrosine residues. This phosphorylation event is indispensable for the interaction of ΔNp63αwith the p300 acetyl-transferases; acetylation of
ΔNp63α result in its stabilization and transcriptional activation. In the absence of FGF8, or in the presence of p63mutations, like the SHFM-associated K193Emutation, this
signaling pathway is not active leading to improper expression of genes involved in limb development. This pathway could be relevant for correct AER stratiﬁcation (in the
scheme marked in yellow) ensuring correct limb outgrowth.
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We show here that lysine K193 of ΔNp63α is acetylated by
p300, in human cells and in vitro.
This has important implications in the pathogenesis of the
SHFM-IV syndrome, since this residue is foundmutated into glu-
tamic acid (K193E) in patients affected by this syndrome (7,8).
Indeed, we found that the K193E mutant ΔNp63α protein is
unable to activate p63 target genes required for developmental
(such as PERP, EGFR) or apoptotic processes (CASP10). Indeed,
programed cell death and cell differentiation are relevant to en-
sure correct shape of the limb (56). In particular, at early stages
of limb development, the anterior and posterior necrotic zones
are essential regions regulating the number of digits (57). On
the other hand, the ΔNp63α-K193E mutant correctly induced
the expression of genes connected to cell-cycle regulation (such
as p53 and p57KIP2) efﬁciently as the wild-type ΔNp63α protein.
We found that, the altered transactivation activity of mutant
ΔNp63α-K193E on target genes involved in developmental or
apoptotic processes, is possibly due to a signiﬁcant decrease in
the DNA binding activity on the RE of such promoters, while
this natural mutant was found to bind normally to the promoter
of the p53 gene. However, it is not clear how this mutation could
alter the binding of ΔNp63α in a promoter-speciﬁc manner.
The role of FGF signaling in the SHFMmalformation has been
partly clariﬁed. It is well established that FGF10 and FGF8 signal-
ing are essential for AER induction and maintenance and that
FGF8, expressed by the AER cells, is the key morphogen for limb
bud outgrowth and patterning. Indeed FGF8 knock-out mice dis-
play severe defects in skeletal and limb development (19–22). The
complete loss of p63, or the knock-in mousemodel for the R279H
mutation, associated to the EEC syndrome, leads to an evident
downregulation of FGF8 expression in the AER cells (3,4,9,46
and data not shown). Likewise, FGF8 is downregulated in the
AER of embryos carrying the combined loss of Dlx5; Dlx6; two
transcription factors causally implicated in SHFM type-I (55).
Dlx5 and Dlx6 proteins co-localize with ΔNp63α in the AER cells
and are direct ΔNp63α targets (46). Hence, the emerging picture
is that FGF8 serves a double function, (a) a morphogen driving
limb growth and patterning, via its actions on mesenchymal
cells (paracrine) and AER cells (autocrine), (b) as stabilizer of
ΔNp63α, to ensure the transitory stratiﬁcation of the AER cells
and the expression of limb-related p63 target genes.
In summary, the work presented here sheds new light on an
important regulatory loop activated by FGF8 essential for
ΔNp63α activation and stabilization in cell cultures and in mice
limb buds and on the molecular mechanism that could be at
the bases of the SHFM-IV pathogenesis.
Experimental procedures
Plasmids
All expression vectors encoding ΔNp63α wild-type and mutant
proteins, p300 cDNAs, c-Abl and shAbl have been previously de-
scribed (36,58). The shRNA against p300 (shp300) and control
shRNA (shLuc) were purchased from Origene.
Cell culture and transfection
U2OS and HaCaT cells were kept in DMEM supplemented with
10% FBS (Euroclone) at 37°C in a humiﬁed atmosphere of 5% (v/v)
CO2 in air.
For transient transfection, 50 000 cells were seeded into
24-multiwell plates and on the next day transfectedwith Lipofec-
tamine 2000 (Invitrogen) or Lipofectamine LTX (Invitrogen) for
HaCaT cell, under the conditions suggested by themanufacturer.
Transfection efﬁciency was checked by transfection of β-gal or
GFP expression vectors. The total amount of transfected DNA
(500 ng for 50 000 cells) was kept constant using empty vector
as necessary.
For stable transfection 300 000HaCaTorU2OS cellswere plated
in sixwells and on the next day, HaCaT cellswere transfectedwith
3 μg of shAbl or 3 μg of shLuc using Lipofectamine LTX (Invitrogen).
After 24 h, cells were trypsinized and plated in amedium contain-
ing puromycin (0.8 μg/ml; Sigma). After 8 days of selection, clones
were pooled and kept in puromycin. U2OS cells were transfected
with 3 μg ofΔNp63α orΔNp63α-K193E using Lipofectamine LTX (In-
vitrogen). After 24 h, cells were trypsinized and plated inmedium
containingNeomicin (G-418, 600 μg/ml).After 3weeks of selection,
clones were pooled and kept in Neomicinat 300 μg/ml.
U2OS and HaCaT cells were treated with 0.5 or 1 m Valproic-
Acid (VPA), 5 ng/ml or 10 ng/ml Trichostatin (TSA), 0.5 or 1 ng/ml
FGF8 or FGF2, 10 μMCHX for the indicated times. For FGF2 or FGF8
treatments, cells were starved for 12 h before treatments using
DMEM supplemented with 0.5% of FBS. HaCaT and U2OS cells
were treated with 5 μM or 10 μM Imatinib, (Sigma) for the indi-
cated times.
Western blot and antibodies
24 h after transfection, cells were lysed in 100 μl of Loading Buffer
2X (2% sodium dodecyl sulfate, 30% glycerol, 144 m β-mercap-
toethanol, 100 m Tris–HCl pH 6.8 and 0.1% Bromo-Phenol
Blue). Samples were incubated at 98°C for 10 min and resolved
by SDS-PAGE. Proteins were transferred to a nitrocellulose mem-
brane (Protran, Millipore). The blots were incubated with the fol-
lowing antibodies (p63 4A4 sc-8431, Santa Cruz Biotechnology),
p300 (p300 C-20 sc-585, Santa Cruz Biotechnology), c-Abl (A5844,
Sigma), acetylated lysine (#9441, Cell-Signaling) and actin (A2066,
Sigma). We used the following secondary antibodies: α-mouse
(sc-2005, Santa Cruz Biotechnology), α-rabbit (sc-2030, Santa
Cruz Biotechnology). Proteins were visualized by an enhanced
chemi-luminescence method (Genespin) according to manufac-
turer’s instructions.
Luciferase activity assay
For reporter promoter assays, cells were transiently co-
transfected with the DLX5, DLX6, ADA, EGFR and p57KIP2 luci-
ferase-reporter plasmids (23,46–48) and expression plasmids
encoding for ΔNp63α, ΔNp63α-K193E and p300. Cells were
seeded in 24-well plates and transfected using Lipofectamine
2000 (Invitrogen, Life Sciences). At 24 h post-transfection, cell
extracts were prepared with Luciferase lysis buffer (1% Triton
X-100, 25 m Gly-Gly pH 7.8, 15 m MgSO4, 4 m EDTA), and
the luciferase activity was measured using the Beetle Luciferin
Kit (Promega Inc.) on a TD 20/20 luminometer (Turner design).
The results are expressed as relative luciferase activity after
normalization with the beta-Galactosidase plasmid as internal
control. Basal activity of the reporter was set to 1. Each histogram
bar represents the mean of three independent transfection ex-
periments performed in triplicate. Standard deviations are
indicated.
Co-immunoprecipitation
U2OS and HaCaT cells (1.25 × 106/100 mm plate) were transfected
with the indicated vectors. 24 h after transfection cells were har-
vested for whole-cell lysates preparation using RIPA buffer
(10 m Tris–HCl pH 8, 2 m EDTA, 0.1% SDS, 0.1% sodium deox-
ycholate, 140 m NaCl, 1X Triton X-100, supplemented with
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1 m phenylmethylsulfonylﬂuoride and cocktail protease inhi-
bitors, Sigma). Cell lysates were incubated on ice for 20 min, vor-
texed, then centrifuged at 6600 g for 20 min to remove cell debris.
Protein concentrationwas determinedwith the Bradford Reagent
(Sigma). 2 mg of cell lysates were incubated overnight at 4°C with
2 μg of anti-p63 (H-129 sc-8344, Santa Cruz Biotechnology) and
anti-p300 (p300 C-20 sc-585, Santa Cruz Biotechnology). The
immuno-complexes were collected by incubating with a mix of
Protein A Agarose and Protein G Sepharose (Sigma) overnight at
4°C. The beads were washed three times: the ﬁrst wash with
RIPA buffer and the others with PBS. The beads were then re-
suspended in 2X Loading buffer, heated at 98°C and loaded on a
SDS polyacrylamide gel and subjected to western blotting with
the indicated antibodies.
RNA extraction and real-time qPCR
For quantitative Real-Time qPCR total RNA was extracted from
U2OS cells with the TRI Reagent (Sigma). 1 μg of total RNAwas re-
verse-transcribed using SuperScriptIII cDNA Preparation Kit
(Life-Technology). Real-Time quantitative PCR (qPCR) was per-
formed with SybrGreen supermix (BIORAD). Tubulin mRNA was
used for normalization. For Real-Time qPCR reaction the se-
quence of the primer pairs are described in Supplementary
Material, Table S1.
ChIP assay
U2OS cells were used for ChIP assays performed as previously de-
scribed (51). Brieﬂy, after ﬁxing in 1% formaldehyde, cells were
lysed for 5 min in 50 m Tris pH 8.0, 2 m EDTA, 0.1% NP-40,
10% glycerol and supplemented with protease inhibitors (all
from Sigma). Nuclei were re-suspended in 50 m Tris pH8.0, 1%
SDS and 5 m EDTA. Chromatin was sheared by sonication, cen-
trifuged and diluted 10-fold in 50 m Tris, pH 8.0, 0.5% NP-40,
0.2 M NaCl and 0.5 m EDTA. After pre-clearing with a 50% sus-
pension of salmon sperm-saturated protein A, lysates were incu-
bated at 4°C overnight with anti-p63 (H137 sc-8343, Santa-Cruz).
Immune complexes were collectedwith sperm-saturated protein
A, washed three times with high salt buffer (20 m Tris pH 8.0,
0.1% SDS, 1% NP-40, 2 m EDTA and 500 m NaCl), and three
times with Tris/EDTA (TE). Immune complexes were extracted
in TE containing 1% SDS, and protein–DNA cross-links were re-
verted by heating at 65°C overnight. DNA was extracted by phe-
nol–chloroform, and the immunoprecipitated DNA was used in
PCR reaction. PCR reactions were performed for 25–35 cycles of
denaturation at 95°C for 45 s, annealing at 55–57°C for 45 s and ex-
tension at 72°C for 45 s. Primer sequences are reported in Supple-
mentary Material, Table S2.
In vitro acetylation assay
In vitro acetylation assay was performed following instructions
provided by Fluorescent HAT Assay Kit (Active Motif, 56100).
The puriﬁed recombinant p300 catalitic domain was incubated
with acetyl-CoA and speciﬁc synthetic substrate peptides. All
peptides were provided by GeneScript. Sequences are reported
in Figure 3B. For ﬂuorescence reading, a BF10000 Fluorocount
was used.
Statistical analysis
Statistical analyses were performed with one-way ANOVA fol-
lowed by Dunnett’s Multiple Comparison post-test, when needed,
usingGraphPad PRISMversion 5.0 (GraphPad, SanDiego, CA, USA).
In the graphs, * and ** mark statistically signiﬁcant data with a
P < 0.05 and <0.01, respectively. Statistically highly signiﬁcant
data, with a P < 0.001, are marked by ***.
Supplementary Material
Supplementary Material is available at HMG online.
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